Directory of funded grants

Filter by

556 results found

Drug Delivery across the Human Blood-Brain Barrier

  • Program Type

    Platform grants

  • Area of research

    Neurodegeneration

  • Disease Area

    Alzheimer’s

  • Competition

    CQDM - Brain Canada - Focus on Brain

  • Province

    Ontario

  • Start Date

    2015

  • Total Grant Amount

    $1,496,800

  • Health Canada Contribution

    $637,505

Project Overview

Toxic amyloid proteins are known to be a significant contributing factor in the development of Alzheimer’s disease. Abnormal clusters of protein fragments build up between nerve cells in the brainleading to impaired memory. The most important therapies in development currently are biologics, antibodies and peptides that bind and neutralize toxic…

Project Complete

See the project and researchers

Cyto-iGluSnFR: A glutamate biosensor platform for brain diseases

  • Program Type

    Platform grants

  • Area of research

    Neurotechnology

  • Competition

    CQDM - Brain Canada - Focus on Brain

  • Province

    Québec

  • Start Date

    2015

  • Total Grant Amount

    $1,416,375

  • Health Canada Contribution

    $597,292

Project Overview

The team wants to take a new breakthrough technology called Cyto-iGluSnFR (pronounced “sight-oh-eye-glue-sniffer”) and adapt it for the discovery of drugs to treat a variety of brain and eye diseases. Cyto-iGluSnFR is an engineered protein that senses the chemical glutamate, allowing scientists to see and measure the rate by which…

Project Complete

See the project and researchers

‘Best in Class’ Platform for Blood Brain Barrier Delivery of Therapeutics

  • Program Type

    Platform grants

  • Area of research

    Multiple

  • Disease Area

    Brain Cancer

  • Competition

    CQDM - Brain Canada - Focus on Brain

  • Province

    Ontario

  • Start Date

    2015

  • Total Grant Amount

    $1,495,000

  • Health Canada Contribution

    $747,500

Project Overview

The blood-brain barrier (BBB) plays an essential role in protecting the brain from blood-borne diseases. However, it blocks otherwise effective medicine from reaching the brain. Most drugs developed for treatment of central nervous system diseases fail because they aren’t optimally designed to cross the BBB. There is a need to…

Project Complete

See the project and researchers

Antipsychotic treatment in a genetic subtype of schizophrenia: Novel insights from neuroimaging and pharmacogenetics

  • Program Type

    Capacity building grants

  • Area of research

    Mental Health

  • Disease Area

    Mental illness,  Parkinson's

  • Competition

    Bell Mental Health Research Training Awards

  • Province

    Ontario

  • Start Date

    2013

  • Total Grant Amount

    $97,500

  • Health Canada Contribution

    $48,750

Project Overview

Schizophrenia is a common and serious mental illness characterized by psychotic symptoms, social withdrawal and functional disabilities that are generally lifelong. Response to treatment with antipsychotics is variable and the manifestation of common side effects, including serious motor symptoms, is unpredictable. There is growing interest in the clinical and predictive…

Project Complete

See the project and researchers

Building the Rick Hansen Alberta Spinal Cord Injury Registry

  • Program Type

    Platform grants

  • Area of research

    Injury

  • Disease Area

    Other

  • Competition

    2014 Platform Grants

  • Province

    Alberta

  • Start Date

    2014

  • Total Grant Amount

    $832,395

  • Health Canada Contribution

    $416,197

Project Overview

There are an estimated 86,000 people living with a spinal cord injury (SCI) in Canada, with an annual economic burden of $2.67 billion for those surviving the initial injury. Approximately half of SCIs are the result of a traumatic (T) incident (ex. motor vehicle accident, sports injury) and the other…

Project Complete

See the project and researchers